The Pure ChainMOTS-C
Regulatory status
Not an approved drug substance in the United States and not on the 503A bulks list. Available to verified facilities for research and manufacturing use only.
Summary
MOTS-C is a sixteen-residue mitochondrial-derived peptide. At this length the synthesis is long enough that deletion sequences accumulate, and purity above 98 percent requires a genuine preparative purification step rather than a single crude pass.
Manufacturers differ substantially in whether they report the deletion sequence profile at all. Where it is absent we do not accept the purity figure as comparable to lots where it is reported.
Typical related substances
Typical related substances are single and double deletion sequences, oxidised methionine variants and residual acetate and water.
Regulatory note
Not an approved drug substance in the United States and not on the 503A bulks list.
Regulatory status shown is our current understanding and is not legal advice. Each facility is responsible for confirming eligibility for its own licence type before purchase.